as strength in its oncology business offset weak China sales, but warned of a potential fine from a drug-import probe in the country. The results lifted AstraZeneca’s shares, which rose as much ...
AstraZeneca said it forecasts sales and earnings growth this year after fourth-quarter results beat expectations, as strength in its oncology business offset weak China sales, but warned of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback